Marie Kosco-Vilbois

This inventor holds 30 USPTO granted patents and 11 published patent applications, plus 8 CIPO patents and 11 EPO patents, primarily in Antibody Therapeutics. Top assignees: Novimmune Sa, Laboratoires Serono S.a., Merck Serono S. a.. Active years: 2008-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marie Kosco-Vilbois. Retrieved from https://idiyas.com/inventor/marie-kosco-vilbois

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 11)

% Patents Active = 76.7

CIPO Patents = 8 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 10)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 224(Granted Patents)

Company Filing History:

Laboratoires Serono S.a.

Years Active: 2008-2023

Loading Chart...

Areas of Expertise:

Anti-CD47 Antibodies

Anti-IL-6 Antibodies

Anti-TLR4 Antibodies

Anti-CD3 Antibodies

Synthetic Polypeptide Libraries

Chemokine Mutants

Autoimmune Diseases

IP-10 Antibodies

RANTES Antibodies

CXCR3-Binding Antagonists

MCP Proteins

Oral Bioavailability

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11840553 - Anti-CD47 antibodies and methods of use thereof (2023-12-12),

2. 11613582 - Anti-IL-6/IL-6R antibodies and methods of use thereof (2023-03-28),

3. 11059910 - Anti-CD47 antibodies and methods of use thereof (2021-07-13),

4. 10982004 - Anti-TLR4 antibodies and uses thereof (2021-04-20),

5. 10759862 - Anti-IL-6/IL-6R antibodies and methods of use thereof (2020-09-01),

6. 10759858 - Anti-CD3 antibodies and methods of use thereof (2020-09-01),

7. 10421809 - Anti-TLR4 antibodies and uses thereof (2019-09-24),

8. 10400044 - Anti-TLR4 antibodies and uses thereof (2019-09-03),

9. 9850304 - Anti-CD3 antibodies and methods of use thereof (2017-12-26),

10. 9828430 - Anti-IL-6/IL-6R antibodies (2017-11-28),

11. 9512221 - Anti-TLR4 antibodies and methods of use thereof (2016-12-06),

12. 9453076 - Anti-TLR4 antibodies and uses thereof (2016-09-27),

13. 9234034 - Methods of treating autoimmune diseases using anti-IL6/IL-6R complex antibodies (2016-01-12),

14. 8921281 - Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants (2014-12-30),

15. 8734790 - Anti-TLR4 antibodies and methods of use thereof (2014-05-27),

Title: **Marie Kosco-Vilbois: Pioneering Innovations in Monoclonal Antibodies**

Introduction

Marie Kosco-Vilbois, hailing from Minzier, France, is a distinguished inventor renowned for her significant contributions to the field of monoclonal antibodies. With a remarkable portfolio of 30 patents, she has been instrumental in advancing therapeutic solutions that target various cellular mechanisms, thus making substantial impacts in the biomedical arena.

Latest Patents

Among her latest patents are groundbreaking inventions, such as anti-CD47 antibodies and methods of use thereof. This invention involves the development of monoclonal and/or monovalent antibodies that effectively bind to CD47, as well as antibodies that target CD19. Additionally, it includes the innovation of bispecific monoclonal antibodies, designed to exhibit different specificities for each binding site on the immunoglobulin molecule, with one site targeting CD47 and another targeting CD19. Another notable patent pertains to anti-IL-6/IL-6R antibodies and their methods of use, which encompass fully human monoclonal antibodies capable of recognizing the IL-6/IL-6R complex. These advances pave the way for therapeutic, diagnostic, and prophylactic applications in modern medicine.

Career Highlights

Throughout her illustrious career, Marie has held pivotal roles in several esteemed organizations. Notably, she has worked with Novimmune SA, where her research contributed significantly to the development of innovative therapeutic solutions. Additionally, her tenure at Laboratoires Serono S.A. further showcases her commitment to pushing the boundaries of scientific research in the biopharmaceutical sector.

Collaborations

Marie Kosco-Vilbois has collaborated with outstanding professionals throughout her career. Among her notable coworkers are Nicolas Fischer and Greg Elson, who have shared in her vision of advancing healthcare through innovation. Their collective expertise has enhanced the development and implementation of cutting-edge antibody therapies.

Conclusion

In conclusion, Marie Kosco-Vilbois stands out as a leading figure in the field of monoclonal antibody research. Her extensive patent portfolio and collaborative efforts reflect her dedication to scientific advancement and innovation within the biomedical field. Through her work, she continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.